8-K: BridgeBio Reports $36.7 Million in Attruby Net Product Revenue for First Quarter 2025, Pipeline Progress Highlighted

BridgeBio announces first quarter 2025 financial results, highlighted by $36.7 million in Attruby net product revenue and advancements in key pipeline programs.

Summary

• BridgeBio Pharma reported its first quarter 2025 financial results and provided business updates.
• Attruby net product revenue reached $36.7 million in its first full quarter of U.S. sales.
• As of April 25, 2025, 2,072 unique patient prescriptions for Attruby were written by 756 unique healthcare providers.
• A Phase 2 trial for hypochondroplasia is fully enrolled ahead of schedule, and the first participant has been dosed in the interventional study.
• A proof-of-principle study of encaleret in hypoparathyroidism showed that 78% of participants achieved normal calcium levels within 5 days.
• The company intends to advance encaleret development for registration in chronic hypoparathyroidism.
• BridgeBio ended the quarter with $540.6 million in cash and cash equivalents.
• An additional $105 million in regulatory milestone payments is expected in Q2 for ex-U.S. approvals of BEYONTTRA.
• Revenues for the quarter were $116.6 million, compared to $211.1 million for the same period in the prior year.
• The net loss attributable to common stockholders was $167.4 million, or $0.88 per share.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While Attruby's commercial performance is positive and clinical trials are progressing, the increased net loss and decreased revenues compared to the prior year temper the overall sentiment. The successful capital raise and anticipated milestone payments provide a degree of financial stability.

Positives

• Attruby's commercial launch is progressing well, with significant revenue generation and increasing prescriptions.
• Clinical trials for hypochondroplasia and hypoparathyroidism are showing promising results.
• Regulatory approvals for BEYONTTRA in the EU, UK, and Japan position it as a global therapy for ATTR-CM.
• The company has a strong cash position, further bolstered by anticipated milestone payments.
• The company has reached regulatory alignment with the FDA on the clinical development plan for infigratinib in children with achondroplasia from birth to less than 3 years old.
• Recent interactions with the FDA indicate alignment on an Accelerated Approval pathway based on the ongoing CANaspire trial for BBP-812 in Canavan disease using urine NAA as a surrogate endpoint.

Negatives

• Revenues decreased by $94.5 million compared to the same period in the prior year, primarily due to a decrease in license and services revenue.
• The company recorded a net loss attributable to common stockholders of $167.4 million, compared to $35.2 million for the same period in the prior year.
• Operating costs and expenses increased by $10.2 million for the three months ended March 31, 2025, compared to the same period in the prior year.

Risks

• The company's future financial performance depends on the continued commercial success of Attruby and the successful development and approval of its pipeline candidates.
• Clinical trial results may not be indicative of final data, and regulatory approvals are not guaranteed.
• Macroeconomic and geopolitical events could impact business operations and expectations.
• The company operates in a competitive and rapidly changing environment.

Future Outlook

The company expects to dose the first participant in the ACT-EARLY Phase 3 study in 2025 and anticipates topline data readouts for several key programs in the second half of 2025 and early 2026. They also anticipate $105 million in regulatory milestone payments in Q2 for ex-U.S. approvals of BEYONTTRA.

Management Comments

• 'Im grateful that Attruby has found a place and is continuing to grow in the front line of the ATTR-CM paradigm,' said Neil Kumar, Ph.D., CEO and founder of BridgeBio.
• Neil Kumar also stated that the success of Attruby is due to its stellar clinical efficacy, safety profile, and the access work done to ensure patients in need can get the drug.
• Neil Kumar also stated that he is pleased to observe the company's continued distinctive performance in clinical development.

Industry Context

BridgeBio is focused on developing therapies for genetic diseases, a growing area of interest in the biopharmaceutical industry. The success of Attruby and the progress of its pipeline programs position the company as a key player in this space. The company's focus on rare diseases aligns with a broader industry trend towards developing treatments for underserved patient populations.

Comparison to Industry Standards

• The $36.7 million in first-quarter sales of Attruby is a strong start compared to similar rare disease drug launches.
• Companies like Alnylam Pharmaceuticals with Onpattro, another ATTR amyloidosis treatment, saw similar initial uptake, suggesting a comparable market opportunity.
• The speed of enrollment in BridgeBio's clinical trials, particularly the hypochondroplasia trial, is faster than industry averages, indicating efficient trial management.
• The 78% success rate in the encaleret Phase 2 study for hypoparathyroidism is promising compared to existing treatments and those in development by competitors like Ascendis Pharma.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the financial performance and the progress of the company's pipeline.
• Patients with genetic diseases stand to benefit from the development and approval of new therapies.
• Employees are affected by the company's financial stability and growth prospects.
• The company's financial performance and clinical trial outcomes could impact investor confidence.

Next Steps

• Dosing the first participant in the ACT-EARLY Phase 3 study in 2025.
• Reporting topline data readouts for FORTIFY, CALIBRATE, and PROPEL 3 in the second half of 2025 and early 2026.
• Initiating clinical development of infigratinib in children with achondroplasia from birth to less than 3 years old by the end of the year.
• Completing enrollment for BBP-812 in the CANaspire pivotal Phase 1/2 study in Canavan disease.
• Advancing encaleret development to enable registration in chronic hypoparathyroidism.

Key Dates

Keywords

BridgeBio, Attruby, Acoramidis, BEYONTTRA, Financial Results, Clinical Trials, Hypochondroplasia, Hypoparathyroidism, LGMD2I/R9, Canavan Disease, ATTR-CM